Авторы

  • Хусанов Р.A.

Ключевые слова:

инфаркт миокарда, внеклеточный матрикс, миокардиальный фиброз.

Библиографические ссылки

Ali M.A.M., Garcia-Vilas J.A., Cromwell C.R., Hubbard B.P., Hendzel M.J., Schulz R. Matrix Metalloproteinase-2 Mediates Ribosomal RNA Transcription by Cleaving Nucleolar Histones. FEBS J. 2021. Vol. 288. P. 6736–6751. doi: 10.1111/febs.16061.

Baghirova S., Hughes B.G., Poirier M., Kondo M.Y., Schulz R. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. J. Mol. Cell. Cardiol. 2016. Vol. 94. P. 153–161. doi: 10.1016/j.yjmcc.2016.04.004.

Bassiouni W., Ali M.A.M., Schulz R. Multifunctional Intracellular Matrix Metalloproteinases: Implications in Disease. FEBS J. 2021. Vol. 288. P. 7162–7182. doi: 10.1111/febs.15701.

Bencsik P., Kupai K., Gorbe A., Kenyeres E., Varga Z.V., Paloczi J., Gaspar R., Kovacs L., Weber L., Takacs F., et al. Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection. Front. Pharmacol. 2018. Vol. 9. P. 296. doi: 10.3389 /fphar.2018.00296.

Botker H.E., Hausenloy D., Andreadou I., Antonucci S., Boengler K., Davidson S.M., Deshwal S., Devaux Y., Di Lisa F., Di Sante M., et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res. Cardiol. 2018. Vol. 113. P. 39. doi: 10.1007/s00395-018-0696-8.

Braidotti N., Chen S.N., Long C.S., Cojoc D., Sbaizero O. Piezo1 Channel as a Potential Target for Hindering Cardiac Fibrotic Remodeling. Int. J. Mol. Sci. 2022 Jul 22; 23(15):8065. doi: 10.3390 /ijms 23158065.

Burke R.M., Burgos Villar K.N., Small E.M. Fibroblast contributions to ischemic cardiac remodeling. Cell Signal. 2021 Jan; 77:109824. doi: 10.1016/ j.cellsig.2020.109824. Epub 2020.

Cautain B., Hill R., de Pedro N., Link W. Components and Regulation of Nuclear Transport Processes. FEBS J. 2015. Vol. 282. P. 445–462. doi: 10.1111/febs.13163.

Castro M.M., Cena J., Cho W.J., Walsh M.P., Schulz R. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arterioscler Thromb Vasc Biol. 2012 Mar. Vol. 32(3). P. 662–668. doi: 10.1161/ATVBAHA.111.242685.

Chan B.Y.H., Roczkowsky A., Cho W.J., Poirier M., Lee T.Y.T., Mahmud Z., Schulz R. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury. Basic Res. Cardiol. 2019. Vol. 114. P. 42. doi: 10.1007/s00395-019-0749-7.

Chang J.H., Huang Y.H., Cunningham C.M., Han K.Y., Chang M., Seiki M., Zhou Z., Azar D.T. Matrix Metalloproteinase 14 Modulates Signal Transduction and Angiogenesis in the Cornea. Surv. Ophthalmol. 2016. Vol. 61. P. 478–497. doi: 10.1016/j.survophthal.2015.11.006.

Czubryt M.P., Hale T.M. Cardiac fibrosis: Pathobiology and therapeutic targets. Cell Signal. 2021 Sep; Vol. 85. P. 110066. doi: 10.1016/ j.cellsig. 2021.110066.

Dobaczewski M., de Haan J.J., Frangogiannis N.G. The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res. 2012 Dec. Vol. 5(6). P. 837–847. doi: 10.1007/s12265-012-9406-3. Epub 2012 Sep 7.

Eshaq R.S., Harris N.R. The Role of Matrix Metalloproteinase 2 (MMP2) In Diabetes-induced Loss of PECAM-1 in The Retina: Direct and Indirect Mechanisms. FASEB J. 2018. Vol. 32. P. 706.2. doi: 10.1096/fasebj.2018.32.1_supplement.706.2.

Goldsmith E.C., Bradshaw A.D., Zile M.R., Spinale F.G. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May. Vol. 70. P. 92–99. doi: 10.1016/j.yjmcc.2014.01.008.

Frangogiannis N.G. Cardiac fibrosis. Cardiovasc Res. 2021 May 25. Vol. 117(6). P. 1450–1488. doi: 10.1093/cvr/cvaa324. PMID: 33135058.

Frangogiannis N.G. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019 Jun 21. Vol. 125(1). P. 117–146. doi: 10.1161/CIRCRESAHA.119.311148.